DUBLIN -- Research and Markets has announced the release of "Dental Pain - Pipeline Review, H1 2013," a report that provides information on the therapeutic development for dental pain, complete with latest updates and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for dental pain.

The scope of the report includes:

- A snapshot of the global therapeutic scenario for Dental Pain.

- A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Involved in Dental Pain Therapeutics Development:

- Novartis AG

- Pfizer Inc.

- IBSA Institut Biochimique SA

- NeuroDiscovery Ltd

- Array BioPharma Inc.

Drug Profiles:

- ARRY-797

- NSL-101

- diclofenac sodium

- SAF-312-A

- PF-05089771

- 29B-S

- 18c-S

- 34B-S

For more information visit https://www.researchandmarkets.com/research/8bzm96/dental_pain.